To the Editor: In the report on their randomized, placebo-controlled, phase 2 trial evaluating bevacizumab, Yang et al. (July 31 issue)¹ conclude that bevacizumab significantly prolongs the time to progression of metastatic renal-cell cancer. I believe this conclusion is inappropriate. Although the patients are randomly assigned to the treatment groups in a randomized phase 2 study, it is not equivalent to a phase 3 study. The purpose of a randomized phase 2 trial is to select one of several novel regimens for the next phase of testing. One can only be reassured that the selected regimen is probably not significantly . . .